1. Home
  2. SWTX
  3. SWTX News

Latest SpringWorks Therapeutics Inc. (SWTX) News on July 1, 2025

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat
SWTX

Insider Monkey

7 days ago

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
SWTX

GlobeNewswire

11 days ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

High Growth Tech Stocks in the US to Watch This May 2025
SWTX

Simply Wall St.

a month ago

High Growth Tech Stocks in the US to Watch This May 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
SWTX

GlobeNewswire

a month ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Biotech Alert: Searches spiking for these stocks today
SWTX

TipRanks

2 months ago

Biotech Alert: Searches spiking for these stocks today

Temu, Tesla prices, Merck KGaA deal: Trending Tickers
SWTX

Yahoo Finance Video

2 months ago

Temu, Tesla prices, Merck KGaA deal: Trending Tickers

Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal
SWTX

The Wall Street Journal

2 months ago

Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
SWTX

GlobeNewswire

2 months ago

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
SWTX

GlobeNewswire

2 months ago

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks
SWTX

The Wall Street Journal

2 months ago

Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks

Exploring 3 High Growth Tech Stocks In The US Market
SWTX

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Here's Why We're Not At All Concerned With SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
SWTX

Simply Wall St.

3 months ago

Here's Why We're Not At All Concerned With SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

High Growth Tech Stocks In The US Market March 2025
SWTX

Simply Wall St.

4 months ago

High Growth Tech Stocks In The US Market March 2025

Investors push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% lower this week, company's increasing losses might be to blame
SWTX

Simply Wall St.

4 months ago

Investors push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% lower this week, company's increasing losses might be to blame

Is SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now?
SWTX

Insider Monkey

4 months ago

Is SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now?

SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect
SWTX

GuruFocus.com

4 months ago

SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
SWTX

GlobeNewswire

4 months ago

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
SWTX

PR Newswire

4 months ago

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
SWTX

TipRanks

5 months ago

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon

SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
SWTX

TipRanks

5 months ago

SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25
SWTX

TipRanks

5 months ago

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
SWTX

GlobeNewswire

5 months ago

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
SWTX

GlobeNewswire

5 months ago

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Germany’s Merck in Talks to Buy SpringWorks Therapeutics
SWTX

The Wall Street Journal

5 months ago

Germany’s Merck in Talks to Buy SpringWorks Therapeutics

High Growth Tech Stocks To Watch In February 2025
SWTX

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In February 2025

Analysts Expect Breakeven For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Before Long
SWTX

Simply Wall St.

5 months ago

Analysts Expect Breakeven For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Before Long

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
SWTX

GlobeNewswire

5 months ago

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
SWTX

Investor's Business Daily

6 months ago

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
SWTX

GlobeNewswire

6 months ago

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim
SWTX

TipRanks

6 months ago

SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim

SpringWorks Therapeutics Stock Gets A RS Rating Lift
SWTX

Investor's Business Daily

6 months ago

SpringWorks Therapeutics Stock Gets A RS Rating Lift

High Growth Tech Stocks to Watch in January 2025
SWTX

Simply Wall St.

6 months ago

High Growth Tech Stocks to Watch in January 2025

SpringWorks Therapeutics price target lowered to $55 from $58 at BofA
SWTX

TipRanks

6 months ago

SpringWorks Therapeutics price target lowered to $55 from $58 at BofA

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SWTX

GlobeNewswire

6 months ago

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

High Growth Tech Stocks to Watch in December 2024
SWTX

Simply Wall St.

7 months ago

High Growth Tech Stocks to Watch in December 2024

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SWTX

GlobeNewswire

7 months ago

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report
SWTX

Simply Wall St.

8 months ago

Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report

SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
SWTX

GuruFocus.com

8 months ago

SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
SWTX

TipRanks

8 months ago

SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result
SWTX

GuruFocus.com

8 months ago

Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

High Growth Tech Stocks To Watch In November 2024
SWTX

Simply Wall St.

8 months ago

High Growth Tech Stocks To Watch In November 2024

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans
SWTX

Simply Wall St.

8 months ago

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
SWTX

GlobeNewswire

8 months ago

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

SpringWorks Therapeutics Inc (SWTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
SWTX

GuruFocus.com

9 months ago

SpringWorks Therapeutics Inc (SWTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

High Growth Tech Stocks in the United States for October 2024
SWTX

Simply Wall St.

9 months ago

High Growth Tech Stocks in the United States for October 2024

Even though SpringWorks Therapeutics (NASDAQ:SWTX) has lost US$229m market cap in last 7 days, shareholders are still up 49% over 5 years
SWTX

Simply Wall St.

9 months ago

Even though SpringWorks Therapeutics (NASDAQ:SWTX) has lost US$229m market cap in last 7 days, shareholders are still up 49% over 5 years

SpringWorks Therapeutics Inc (SWTX) CEO Saqib Islam Sells 49,000 Shares
SWTX

GuruFocus.com

10 months ago

SpringWorks Therapeutics Inc (SWTX) CEO Saqib Islam Sells 49,000 Shares

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
SWTX

GlobeNewswire

10 months ago

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

High Growth Tech Stocks to Watch in August 2024
SWTX

Simply Wall St.

10 months ago

High Growth Tech Stocks to Watch in August 2024

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
SWTX

Simply Wall St.

a year ago

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX): Is Breakeven Near?
SWTX

Simply Wall St.

a year ago

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX): Is Breakeven Near?

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
SWTX

GuruFocus.com

a year ago

Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)

Insider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX)
SWTX

GuruFocus.com

a year ago

Insider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX)

Insider Sale: CEO Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX)
SWTX

GuruFocus.com

a year ago

Insider Sale: CEO Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX)

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
SWTX

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SWTX

GuruFocus.com

a year ago

SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
SWTX

GuruFocus.com

a year ago

SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

SpringWorks Therapeutics to Present at Upcoming Investor Conferences
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

SpringWorks Therapeutics Inc Insider Sells Company Shares
SWTX

GuruFocus.com

a year ago

SpringWorks Therapeutics Inc Insider Sells Company Shares

SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
SWTX

GuruFocus.com

a year ago

SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares

Southwest Airlines (LUV) to Add More Routes to Las Vegas
SWTX

Zacks

a year ago

Southwest Airlines (LUV) to Add More Routes to Las Vegas

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
SWTX

GlobeNewswire

a year ago

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Here's Why Urban Outfitters (URBN) Gained But Lagged the Market Today
SWTX

Zacks

a year ago

Here's Why Urban Outfitters (URBN) Gained But Lagged the Market Today

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30
SWTX

CNW Group

a year ago

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030
SWTX

GlobeNewswire

a year ago

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

SWTX

Business Wire

a year ago

Form 8.3 - DX (Group) plc

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis
SWTX

GlobeNewswire

a year ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

Does Wingstop (NASDAQ:WING) Deserve A Spot On Your Watchlist?
SWTX

Simply Wall St.

a year ago

Does Wingstop (NASDAQ:WING) Deserve A Spot On Your Watchlist?

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.
SWTX

Motley Fool

a year ago

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

4 Reasons to Buy Opendoor Stock
SWTX

Motley Fool

a year ago

4 Reasons to Buy Opendoor Stock

Better AI Buy: AMD vs. Symbotic Stock
SWTX

Motley Fool

a year ago

Better AI Buy: AMD vs. Symbotic Stock

Bundle and Save with Boost Mobile: Get the Summit Flip and One Year of Service for Only $129, Exclusively at Walmart
SWTX

PR Newswire

a year ago

Bundle and Save with Boost Mobile: Get the Summit Flip and One Year of Service for Only $129, Exclusively at Walmart

Parker-Hannifin (PH) to Post Q2 Earnings: Is a Beat in Store?
SWTX

Zacks

a year ago

Parker-Hannifin (PH) to Post Q2 Earnings: Is a Beat in Store?

SWTX

Thomson Reuters StreetEvents

a year ago

Q4 2023 CNX Resources Corp Earnings Call

Home Depot (HD) Rises Higher Than Market: Key Facts
SWTX

Zacks

a year ago

Home Depot (HD) Rises Higher Than Market: Key Facts

California Water Service Group Board of Directors Declares 316th Consecutive Quarterly Dividend and 57th Consecutive Annual Dividend Increase
SWTX

GlobeNewswire

a year ago

California Water Service Group Board of Directors Declares 316th Consecutive Quarterly Dividend and 57th Consecutive Annual Dividend Increase

Tesla Stock Slides After EV Maker Projects Slower Growth
SWTX

The Wall Street Journal

a year ago

Tesla Stock Slides After EV Maker Projects Slower Growth

CNX Resources (CNX) Q4 Earnings Beat Estimates, Revenues Lag
SWTX

Zacks

a year ago

CNX Resources (CNX) Q4 Earnings Beat Estimates, Revenues Lag

Janus Henderson Group plc (JHG) Expected to Beat Earnings Estimates: Should You Buy?
SWTX

Zacks

a year ago

Janus Henderson Group plc (JHG) Expected to Beat Earnings Estimates: Should You Buy?

Valley National (VLY) Reports Q4 Earnings: What Key Metrics Have to Say
SWTX

Zacks

a year ago

Valley National (VLY) Reports Q4 Earnings: What Key Metrics Have to Say

IHG’s New Americas CEO: A Bet on Luxury and Moving at ‘China Speed’
SWTX

Skift

a year ago

IHG’s New Americas CEO: A Bet on Luxury and Moving at ‘China Speed’

Share on Social Networks: